HC Wainwright Reaffirms “Neutral” Rating for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN)‘s stock had its “neutral” rating restated by investment analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports.

Agenus Trading Up 2.7 %

AGEN stock opened at $3.76 on Wednesday. The firm has a 50-day moving average of $3.16 and a two-hundred day moving average of $5.02. The firm has a market capitalization of $88.21 million, a PE ratio of -0.33 and a beta of 1.27. Agenus has a one year low of $2.50 and a one year high of $19.69.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Point72 DIFC Ltd acquired a new stake in Agenus during the 2nd quarter worth about $51,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Agenus during the second quarter valued at approximately $106,000. HighTower Advisors LLC increased its stake in Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 7,530 shares during the period. Exchange Traded Concepts LLC boosted its stake in shares of Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after buying an additional 9,422 shares during the period. Finally, State Street Corp grew its holdings in shares of Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after acquiring an additional 9,731 shares in the last quarter. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.